James Crowe

[James Crowe @croweje]

@celinegounder @EricTopol @VUMC_Vaccines I agree we need to prepare for obvious threats ahead of time, instead of waiting for disaster to strike. Which is why we have launched the AHEAD100 program to stockpile broad and potent human mAbs for the 100 most likely causes of future epidemics.https://t.co/khG8jxHajd

[James Crowe @croweje]

@andrabi_raiees @aaronmring @VirusesImmunity @brett_lindenbac @NathanGrubaugh @EOSaphire @profvrr LS modification of Fc is principally used to modulate the half life of IgGs. But the concept is there, that with (other) Fc mutations one can greatly reduce Fc interaction with FcRs.

[James Crowe @croweje]

@davidrwilson @VirusesImmunity @NathanGrubaugh @aaronmring @EOSaphire @brett_lindenbac @profvrr Phase I trials for the first mRNA encoded human mAb (our chikungunya mAb) are already completed. mRNA is the only real answer for ultra-rapid response. https://t.co/ykQy9gJJEz

[James Crowe @croweje]

@VirusesImmunity @NathanGrubaugh @aaronmring @EOSaphire @brett_lindenbac @profvrr Yes, these are the issues. After infection the treatment window is short. And CNS infections are difficult to treat, as the BBB is an obstacle. We are actively working on adding domains to our mAbs to facilitate active transport into brain.

[James Crowe @croweje]

Rosetta computational design can increase the breadth of human monoclonal antibodies, in this case to influenza

#flu #monoclonalantibodies https://t.co/rhbWsEdJ7a

[James Crowe @croweje]

4-Å-resolution cryo-electron microscopy structure of the ZIKV virion in complex with Fab fragments of our potently neutralizing human monoclonal antibody ZIKV-195, with Rossmann lab @ Purdue

#electronmicroscopy #zika #fab #struct…https://t.co/ZLrh9pk17P https://t.co/9OdIafbApN

[James Crowe @croweje]

@MikeLaCrosseWBZ wondering if I could chat briefly with you on Powassan virus